<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057330</url>
  </required_header>
  <id_info>
    <org_study_id>208141/039</org_study_id>
    <secondary_id>01-643</secondary_id>
    <nct_id>NCT00057330</nct_id>
  </id_info>
  <brief_title>HerpeVac Trial for Young Women</brief_title>
  <official_title>A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who Are HSV-1 and -2 Seronegative</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to see if a herpes vaccine may prevent genital herpes
      disease in women who are not infected. The study will enroll approximately 7550 healthy
      women. These women will be randomly assigned to 1 of 2 possible study groups: herpes vaccine
      (experimental group) or hepatitis A vaccine (control group). Participants will receive their
      assigned vaccine at 0, 1, and 6 months. Participants will have 9 scheduled study visits and
      additional unscheduled visits for an evaluation of herpes if it is suspected. Participants
      will be involved in study related procedures for up to 20 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blind, randomized, controlled Phase III trial to assess the
      prophylactic efficacy and safety of gD-Alum/MPL vaccine in the prevention of genital herpes
      disease in young women who are herpes simplex virus (HSV)-1 and -2 seronegative. The primary
      efficacy objective is to evaluate vaccine efficacy in the prevention of genital herpes
      disease caused by HSV-1 and/or HSV-2 between months 2 and 20 in healthy adult women who were
      initially HSV-1 and HSV-2 seronegative. The secondary efficacy objectives are to: evaluate
      vaccine efficacy in the prevention of genital herpes disease caused by HSV-1 and/or HSV-2
      occurring between the months 7 and 20; evaluate vaccine efficacy in the prevention of HSV-2
      infection between months 2 and 20; and to evaluate vaccine efficacy in the prevention of
      HSV-2 infection occurring between months 7 and 20. The study will enroll approximately 7,550
      women, ages 18-30 years. Participants will be randomized to 1 of 2 possible study groups:
      candidate vaccine; or control vaccine (hepatitis A vaccine). The study duration for each
      subject will be approximately 20 months. Study procedures will include 9 scheduled study
      visits (including the screening visit) and additional unscheduled visits for evaluation of
      suspected herpes disease episodes. Three doses of vaccine or control will be administered
      intramuscularly in the non-dominant deltoid on a 0, 1, and 6 month schedule. Subjects will
      attend clinic visits at screening, months 2, 7, 12, 16, and 20. In subjects who present with
      suspected herpes disease between months 17 and 20, an additional visit to collect a serum
      sample will be scheduled 3 months after the evaluation for suspected genital herpes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Newly Acquired Genital Herpes Disease, Caused by Either Herpes Simplex Virus (HSV)-1 or HSV-2</measure>
    <time_frame>Between Months 2 and 20</time_frame>
    <description>Genital herpes disease was defined as signs (swelling, papules, vesicles, ulcers, crusts, fissures, erythema, or vaginal discharge) and/or symptoms (pain, burning, itching, tingling, dysuria) which developed on the skin or mucosa of the anogenital region and/or buttocks and laboratory confirmation of Herpes Simplex Virus (HSV)-1 or 2 infection (either concomitant positive HSV culture or HSV seroconversion within 6 months after onset of signs and/or symptoms). Seroconversion to HSV-1 and/or HSV-2 was defined as a positive HSV-1 and/or HSV-2 Western blot in a subject with a previously negative Western blot result for the corresponding HSV type.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Newly Acquired Genital Herpes Disease, Caused by Either Herpes Simplex Virus (HSV)-1 or HSV-2</measure>
    <time_frame>Between Months 7 and 20</time_frame>
    <description>Genital herpes disease was defined as signs (swelling, papules, vesicles, ulcers, crusts, fissures, erythema, or vaginal discharge) and/or symptoms (pain, burning, itching, tingling, dysuria) which developed on the skin or mucosa of the anogenital region and/or buttocks and laboratory confirmation of Herpes Simplex Virus (HSV)-1 or 2 infection (either concomitant positive HSV culture or HSV seroconversion within 6 months after onset of signs and/or symptoms). Seroconversion to HSV-1 and/or HSV-2 was defined as a positive HSV-1 and/or HSV-2 Western blot in a subject with a previously negative Western blot result for the corresponding HSV type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Newly Acquired Herpes Simplex Virus (HSV)-2 Infection Confirmed by Either Virus Culture or HSV-2 Seroconversion.</measure>
    <time_frame>Between Months 2 and 20</time_frame>
    <description>The number of subjects with newly acquired HSV-2 infection confirmed by either virus culture or HSV-2 seroconversion was tabulated. Seroconversion to HSV-1 and/or HSV-2 was defined as a positive HSV-1 and/or HSV-2 Western blot in a subject with a previously negative Western blot result for the corresponding HSV type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Newly Acquired Herpes Simplex Virus (HSV)-2 Infection Confirmed by Either Virus Culture or HSV-2 Seroconversion</measure>
    <time_frame>Between Months 7 and 20</time_frame>
    <description>The number of subjects with newly acquired HSV-2 infection confirmed by either virus culture or HSV-2 seroconversion was tabulated. Seroconversion to HSV-1 and/or HSV-2 was defined as a positive HSV-1 and/or HSV-2 Western blot in a subject with a previously negative Western blot result for the corresponding HSV type.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations for Anti-glycoprotein D (Anti-gD) Antibodies.</measure>
    <time_frame>At Months 0, 2, 6, 7, 12, 16 and 20</time_frame>
    <description>Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA). Concentrations were expressed as geometric mean concentrations (GMCs) in ELISA units per milliliter (EU/mL). The seroprotection cut-off of the assay was 40 EU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Anti-herpes Simplex Virus (Anti-HSV) Neutralizing Antibodies.</measure>
    <time_frame>At Months 0, 2, 6, 7, 12, 16 and 20</time_frame>
    <description>Titers for Anti-HSV neutralizing antibodies are presented as Geometric Mean Titers (GMTs), and are expressed in Estimated Doses (ED), that is, the reciprocal of the dilution necessary to achieve neutralization. Antibody titers below the lowest level of quantification were not calculated .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and General Symptoms</measure>
    <time_frame>Within 7 days (Days 0-6) after vaccination</time_frame>
    <description>Solicited local symptoms assessed were pain, redness and swelling.
Solicited general symptoms assessed were fatigue, headache, malaise and fever (defined as oral/axillary/tympanic temperature equal to or above 37.5 degrees Celsius).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Grade 3 Solicited Local Symptoms</measure>
    <time_frame>Within 7 days (Days 0-6) after vaccination</time_frame>
    <description>Solicited local symptoms assessed were pain, redness and swelling.
Grade 3 pain = pain that prevented normal activities.
Grade 3 redness/swelling = redness/swelling above 30 mm and persisting for more than 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>Within 7 days (Days 0-6) after vaccination</time_frame>
    <description>Solicited general symptoms assessed were fatigue, headache, malaise and fever (oral/axillary/tympanic).
Grade 3 headache, fatigue, malaise = symptom that prevented normal activities.
Grade 3 fever = temperature above 39.0 degrees Celsius.
Related = symptom assessed by the investigator as causally related to the vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within 31 days after vaccination</time_frame>
    <description>Unsolicited AEs have been tabulated for a 31-day period. An unsolicited AE was any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With New Onset Chronic Diseases (NOCDs), Medically Significant Conditions (MSCs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Throughout the study (From Month 0 up to Month 20)</time_frame>
    <description>NOCDs included adverse events (AEs) as autoimmune disorders, asthma, type I diabetes, allergies. MSCs included AEs prompting emergency room or physician visits unrelated to common diseases or routine visits for physical examination or vaccination, or SAEs unrelated to common diseases. SAEs included medical occurrences either life-threatening, requiring hospitalization, or resulting in death, disability/incapacity or congenital anomaly/birth defect in a subject's offspring. Common diseases included upper respiratory infections (URIs), sinusitis, pharyngitis, gastroenteritis, urinary tract infection, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury. The following were not reported if not considered as SAEs and occurring more than 30 days post vaccination: URIs, sinusitis, pharyngitis, gastroenteritis, injury, or visits for routine physical examination or vaccination. AEs are described, using Medical Dictionary for Regulatory Activities' preferred terms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>Throughout the study (From Month 0 up to Month 20)</time_frame>
    <description>SAEs assessed included medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or were a congenital anomaly/birth defect in a subject's offspring.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8323</enrollment>
  <condition>Herpes Simplex Infection</condition>
  <arm_group>
    <arm_group_label>Herpes Simplex Virus Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus (HSV) vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Havrix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine</intervention_name>
    <description>the vaccine was administered intramuscularly in the non-dominant deltoid</description>
    <arm_group_label>Herpes Simplex Virus Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine</intervention_name>
    <description>the vaccine was administered intramuscularly in the non-dominant deltoid</description>
    <arm_group_label>Havrix Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A female between, and including, 18 and 30 years of age at the time of the first
             vaccination.

          -  Written informed consent obtained from the subject.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

          -  Seronegative for HSV-1 and HSV-2 by Western blot.

          -  Subject must be non-childbearing potential, i.e. either surgically sterilized or, if
             of child bearing potential, she must be using a highly effective method of birth
             control (e.g., intrauterine contraceptive device; oral contraceptives; diaphragm or
             condom in combination with contraceptive jelly, cream or foam; Norplant®;
             DepoProvera®; contraceptive skin patch or cervical ring) for 30 days prior to
             vaccination, have a negative urine pregnancy test and must agree to continue such
             precautions for two months after completion of the vaccination series.

          -  A subject for whom the investigator believes can and will comply with the requirements
             of the protocol (e.g. completion of the memory aid/diary cards, return for follow-up
             visits, accessible by phone or pager, able to self-sample and not planning on moving
             from study area).

        Exclusion Criteria:

          -  Pregnant or nursing female.

          -  Clinical signs or symptoms of current oro-labial, genital or non-genital HSV disease,
             such as swelling, papules, vesicles, pustules, ulcers, crusts, fissures, erythema,
             discharge, pain, burning, itching, tingling or dysuria.

          -  Previous vaccination against herpes.

          -  Previous administration of monophosphoryl lipid A (MPL) adjuvant (no vaccines
             currently licensed in the USA contain this).

          -  History of any confirmed oro-labial, genital or non-genital HSV disease or infection.

          -  Use of any investigational or non-registered drug or vaccine other than the study
             vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use
             during the study period.

          -  Planned administration/ administration of a non-study vaccine within 30 days of the
             first dose of the study vaccine with the following exceptions: Administration of
             routine Meningococcal, Hepatitis B, inactivated Influenza, and Diphtheria/Tetanus
             vaccine up to 8 days before the first dose of study vaccine is allowed.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the study vaccines, e.g. aluminum, MPL, alum-MPL, 2-phenoxyethanol or neomycin.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition including,
             human immunodeficiency virus (HIV) infection.

          -  Acute or chronic, clinically significant (unresolved, requiring on-going medical
             management or medication, etc.) pulmonary, cardiovascular, hepatic or renal function
             abnormality, as determined by medical history or physical examination.

          -  Acute disease at the time of enrollment (defer vaccination until subject recovers).
             Acute disease is defined as the presence of a moderate or severe illness with or
             without fever. Study vaccine can be administered to persons with a minor illness such
             as diarrhea, mild upper respiratory infection with or without low-grade febrile
             illness.

          -  Oral temperature greater than or equal to 99.5º F (greater than or equal to 37.5º C) /
             axillary temperature greater than or equal to 99.5º (greater than or equal to 37.5º C)
             / tympanic temperature on oral setting greater than or equal to 99.5º F (greater than
             or equal to 37.5º C).

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the first vaccine dose. (For
             corticosteroids, this will mean prednisone or, equivalent, greater than or equal to
             0.5 mg/kg/day. Inhaled or topical steroids are allowed.)

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  Recent history of chronic alcohol consumption (defined as more than 5 oz of ethanol
             [absolute alcohol] per day) and/or drug abuse.

          -  History of sexually transmitted infection within 30 days preceding the first dose of
             study vaccine.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2003</study_first_submitted>
  <study_first_submitted_qc>March 31, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2003</study_first_posted>
  <results_first_submitted>September 29, 2011</results_first_submitted>
  <results_first_submitted_qc>September 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 3, 2011</results_first_posted>
  <last_update_submitted>September 29, 2016</last_update_submitted>
  <last_update_submitted_qc>September 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Krestin</mesh_term>
    <mesh_term>Monophosphoryl lipid A</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>8323 subjects were enrolled and vaccinated (4577 in the Herpes Simplex Virus Group and 3746 in the Havrix Group). Out of these, 7850 subjects were followed throughout the entire study, e. a. for safety and adverse event assessment (4488 in the Herpes Simplex Virus Group and 3662 in the Havrix Group).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Herpes Simplex Virus Group</title>
          <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
        </group>
        <group group_id="P2">
          <title>Havrix Group</title>
          <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4577"/>
                <participants group_id="P2" count="3746"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3445"/>
                <participants group_id="P2" count="2826"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1132"/>
                <participants group_id="P2" count="920"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="745"/>
                <participants group_id="P2" count="617"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="260"/>
                <participants group_id="P2" count="206"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Herpes Simplex Virus Group</title>
          <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
        </group>
        <group group_id="B2">
          <title>Havrix Group</title>
          <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4577"/>
            <count group_id="B2" value="3746"/>
            <count group_id="B3" value="8323"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.3" spread="3.30"/>
                    <measurement group_id="B2" value="22.3" spread="3.23"/>
                    <measurement group_id="B3" value="22.3" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4577"/>
                    <measurement group_id="B2" value="3746"/>
                    <measurement group_id="B3" value="8323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Newly Acquired Genital Herpes Disease, Caused by Either Herpes Simplex Virus (HSV)-1 or HSV-2</title>
        <description>Genital herpes disease was defined as signs (swelling, papules, vesicles, ulcers, crusts, fissures, erythema, or vaginal discharge) and/or symptoms (pain, burning, itching, tingling, dysuria) which developed on the skin or mucosa of the anogenital region and/or buttocks and laboratory confirmation of Herpes Simplex Virus (HSV)-1 or 2 infection (either concomitant positive HSV culture or HSV seroconversion within 6 months after onset of signs and/or symptoms). Seroconversion to HSV-1 and/or HSV-2 was defined as a positive HSV-1 and/or HSV-2 Western blot in a subject with a previously negative Western blot result for the corresponding HSV type.</description>
        <time_frame>Between Months 2 and 20</time_frame>
        <population>The Per Protocol cohort for analysis of efficacy (Months 2-20) included all subjects who met inclusion/exclusion criteria, did not meet infection/disease, did not meet censoring criteria, had at least 1 efficacy assessment, received 2 doses of the vaccine within the permitted time interval, with known vaccine administration site and route.</population>
        <group_list>
          <group group_id="O1">
            <title>Herpes Simplex Virus Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Newly Acquired Genital Herpes Disease, Caused by Either Herpes Simplex Virus (HSV)-1 or HSV-2</title>
          <description>Genital herpes disease was defined as signs (swelling, papules, vesicles, ulcers, crusts, fissures, erythema, or vaginal discharge) and/or symptoms (pain, burning, itching, tingling, dysuria) which developed on the skin or mucosa of the anogenital region and/or buttocks and laboratory confirmation of Herpes Simplex Virus (HSV)-1 or 2 infection (either concomitant positive HSV culture or HSV seroconversion within 6 months after onset of signs and/or symptoms). Seroconversion to HSV-1 and/or HSV-2 was defined as a positive HSV-1 and/or HSV-2 Western blot in a subject with a previously negative Western blot result for the corresponding HSV type.</description>
          <population>The Per Protocol cohort for analysis of efficacy (Months 2-20) included all subjects who met inclusion/exclusion criteria, did not meet infection/disease, did not meet censoring criteria, had at least 1 efficacy assessment, received 2 doses of the vaccine within the permitted time interval, with known vaccine administration site and route.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3798"/>
                <count group_id="O2" value="3076"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Newly Acquired Genital Herpes Disease, Caused by Either Herpes Simplex Virus (HSV)-1 or HSV-2</title>
        <description>Genital herpes disease was defined as signs (swelling, papules, vesicles, ulcers, crusts, fissures, erythema, or vaginal discharge) and/or symptoms (pain, burning, itching, tingling, dysuria) which developed on the skin or mucosa of the anogenital region and/or buttocks and laboratory confirmation of Herpes Simplex Virus (HSV)-1 or 2 infection (either concomitant positive HSV culture or HSV seroconversion within 6 months after onset of signs and/or symptoms). Seroconversion to HSV-1 and/or HSV-2 was defined as a positive HSV-1 and/or HSV-2 Western blot in a subject with a previously negative Western blot result for the corresponding HSV type.</description>
        <time_frame>Between Months 7 and 20</time_frame>
        <population>The Per Protocol cohort for analysis of efficacy (Months 7-20) included all subjects who met inclusion/exclusion criteria, did not meet infection/disease, did not meet censoring criteria, had at least 1 efficacy assessment, received 3 doses of the vaccine within the permitted time interval, with known vaccine administration site and route.</population>
        <group_list>
          <group group_id="O1">
            <title>Herpes Simplex Virus Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Newly Acquired Genital Herpes Disease, Caused by Either Herpes Simplex Virus (HSV)-1 or HSV-2</title>
          <description>Genital herpes disease was defined as signs (swelling, papules, vesicles, ulcers, crusts, fissures, erythema, or vaginal discharge) and/or symptoms (pain, burning, itching, tingling, dysuria) which developed on the skin or mucosa of the anogenital region and/or buttocks and laboratory confirmation of Herpes Simplex Virus (HSV)-1 or 2 infection (either concomitant positive HSV culture or HSV seroconversion within 6 months after onset of signs and/or symptoms). Seroconversion to HSV-1 and/or HSV-2 was defined as a positive HSV-1 and/or HSV-2 Western blot in a subject with a previously negative Western blot result for the corresponding HSV type.</description>
          <population>The Per Protocol cohort for analysis of efficacy (Months 7-20) included all subjects who met inclusion/exclusion criteria, did not meet infection/disease, did not meet censoring criteria, had at least 1 efficacy assessment, received 3 doses of the vaccine within the permitted time interval, with known vaccine administration site and route.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3273"/>
                <count group_id="O2" value="2622"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Newly Acquired Herpes Simplex Virus (HSV)-2 Infection Confirmed by Either Virus Culture or HSV-2 Seroconversion.</title>
        <description>The number of subjects with newly acquired HSV-2 infection confirmed by either virus culture or HSV-2 seroconversion was tabulated. Seroconversion to HSV-1 and/or HSV-2 was defined as a positive HSV-1 and/or HSV-2 Western blot in a subject with a previously negative Western blot result for the corresponding HSV type.</description>
        <time_frame>Between Months 2 and 20</time_frame>
        <population>The Per Protocol cohort for analysis of efficacy (Months 2-20) included all subjects who met inclusion/exclusion criteria, did not meet infection/disease, did not meet censoring criteria, had at least 1 efficacy assessment, received 2 doses of the vaccine within the permitted time interval, with known vaccine administration site and route.</population>
        <group_list>
          <group group_id="O1">
            <title>Herpes Simplex Virus Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Newly Acquired Herpes Simplex Virus (HSV)-2 Infection Confirmed by Either Virus Culture or HSV-2 Seroconversion.</title>
          <description>The number of subjects with newly acquired HSV-2 infection confirmed by either virus culture or HSV-2 seroconversion was tabulated. Seroconversion to HSV-1 and/or HSV-2 was defined as a positive HSV-1 and/or HSV-2 Western blot in a subject with a previously negative Western blot result for the corresponding HSV type.</description>
          <population>The Per Protocol cohort for analysis of efficacy (Months 2-20) included all subjects who met inclusion/exclusion criteria, did not meet infection/disease, did not meet censoring criteria, had at least 1 efficacy assessment, received 2 doses of the vaccine within the permitted time interval, with known vaccine administration site and route.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3798"/>
                <count group_id="O2" value="3076"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Newly Acquired Herpes Simplex Virus (HSV)-2 Infection Confirmed by Either Virus Culture or HSV-2 Seroconversion</title>
        <description>The number of subjects with newly acquired HSV-2 infection confirmed by either virus culture or HSV-2 seroconversion was tabulated. Seroconversion to HSV-1 and/or HSV-2 was defined as a positive HSV-1 and/or HSV-2 Western blot in a subject with a previously negative Western blot result for the corresponding HSV type.</description>
        <time_frame>Between Months 7 and 20</time_frame>
        <population>The Per Protocol cohort for analysis of efficacy (Months 7-20) included all subjects who met inclusion/exclusion criteria, did not meet infection/disease, did not meet censoring criteria, had at least 1 efficacy assessment, received 3 doses of the vaccine within the permitted time interval, with known vaccine administration site and route.</population>
        <group_list>
          <group group_id="O1">
            <title>Herpes Simplex Virus Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Newly Acquired Herpes Simplex Virus (HSV)-2 Infection Confirmed by Either Virus Culture or HSV-2 Seroconversion</title>
          <description>The number of subjects with newly acquired HSV-2 infection confirmed by either virus culture or HSV-2 seroconversion was tabulated. Seroconversion to HSV-1 and/or HSV-2 was defined as a positive HSV-1 and/or HSV-2 Western blot in a subject with a previously negative Western blot result for the corresponding HSV type.</description>
          <population>The Per Protocol cohort for analysis of efficacy (Months 7-20) included all subjects who met inclusion/exclusion criteria, did not meet infection/disease, did not meet censoring criteria, had at least 1 efficacy assessment, received 3 doses of the vaccine within the permitted time interval, with known vaccine administration site and route.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3273"/>
                <count group_id="O2" value="2622"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentrations for Anti-glycoprotein D (Anti-gD) Antibodies.</title>
        <description>Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA). Concentrations were expressed as geometric mean concentrations (GMCs) in ELISA units per milliliter (EU/mL). The seroprotection cut-off of the assay was 40 EU/mL</description>
        <time_frame>At Months 0, 2, 6, 7, 12, 16 and 20</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects (meeting eligibility criteria, complying with protocol-defined procedures and not meeting either the infection or disease criteria on or prior to Month 7) for whom data concerning immunogenicity outcome measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Herpes Simplex Virus Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations for Anti-glycoprotein D (Anti-gD) Antibodies.</title>
          <description>Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA). Concentrations were expressed as geometric mean concentrations (GMCs) in ELISA units per milliliter (EU/mL). The seroprotection cut-off of the assay was 40 EU/mL</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects (meeting eligibility criteria, complying with protocol-defined procedures and not meeting either the infection or disease criteria on or prior to Month 7) for whom data concerning immunogenicity outcome measures were available.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="641"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-gD GMCs at Month 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.52" lower_limit="20.77" upper_limit="22.29"/>
                    <measurement group_id="O2" value="20.62" lower_limit="19.94" upper_limit="21.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-gD GMCs at Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3575" lower_limit="3256" upper_limit="3925"/>
                    <measurement group_id="O2" value="21.39" lower_limit="20.33" upper_limit="22.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-gD GMCs at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="681.3" lower_limit="622.1" upper_limit="746.2"/>
                    <measurement group_id="O2" value="21.58" lower_limit="20.42" upper_limit="22.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-gD GMCs at Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6809" lower_limit="6344" upper_limit="7309"/>
                    <measurement group_id="O2" value="21.50" lower_limit="20.36" upper_limit="22.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-gD GMCs at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1805" lower_limit="1667" upper_limit="1955"/>
                    <measurement group_id="O2" value="21.14" lower_limit="19.89" upper_limit="22.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-gD GMCs at Month 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1025" lower_limit="941.9" upper_limit="1115"/>
                    <measurement group_id="O2" value="20.10" lower_limit="19.90" upper_limit="20.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-gD GMCs at Month 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="769.1" lower_limit="704.1" upper_limit="840.0"/>
                    <measurement group_id="O2" value="20.60" lower_limit="19.65" upper_limit="21.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Anti-herpes Simplex Virus (Anti-HSV) Neutralizing Antibodies.</title>
        <description>Titers for Anti-HSV neutralizing antibodies are presented as Geometric Mean Titers (GMTs), and are expressed in Estimated Doses (ED), that is, the reciprocal of the dilution necessary to achieve neutralization. Antibody titers below the lowest level of quantification were not calculated .</description>
        <time_frame>At Months 0, 2, 6, 7, 12, 16 and 20</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects (meeting eligibility criteria, complying with protocol-defined procedures and not meeting either the infection or disease criteria on or prior to Month 7) for whom data concerning immunogenicity outcome measures were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Herpes Simplex Virus Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Anti-herpes Simplex Virus (Anti-HSV) Neutralizing Antibodies.</title>
          <description>Titers for Anti-HSV neutralizing antibodies are presented as Geometric Mean Titers (GMTs), and are expressed in Estimated Doses (ED), that is, the reciprocal of the dilution necessary to achieve neutralization. Antibody titers below the lowest level of quantification were not calculated .</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all evaluable subjects (meeting eligibility criteria, complying with protocol-defined procedures and not meeting either the infection or disease criteria on or prior to Month 7) for whom data concerning immunogenicity outcome measures were available.</population>
          <units>ED</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="641"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HSV GMTs at Month 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" lower_limit="2.04" upper_limit="2.14"/>
                    <measurement group_id="O2" value="2.06" lower_limit="2.00" upper_limit="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HSV GMTs at Month 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.57" lower_limit="6.86" upper_limit="8.34"/>
                    <measurement group_id="O2" value="NA">Antibody titers below the lowest level of quantification were not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HSV GMTs at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" lower_limit="2.31" upper_limit="2.54"/>
                    <measurement group_id="O2" value="NA">Antibody titers below the lowest level of quantification were not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HSV GMTs at Month 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.27" lower_limit="26.59" upper_limit="30.06"/>
                    <measurement group_id="O2" value="2.10" lower_limit="2.00" upper_limit="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HSV GMTs at Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.40" lower_limit="7.63" upper_limit="9.24"/>
                    <measurement group_id="O2" value="2.02" lower_limit="1.99" upper_limit="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HSV GMTs at Month 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" lower_limit="4.32" upper_limit="5.16"/>
                    <measurement group_id="O2" value="2.03" lower_limit="1.98" upper_limit="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HSV GMTs at Month 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" lower_limit="3.37" upper_limit="3.96"/>
                    <measurement group_id="O2" value="2.11" lower_limit="2.01" upper_limit="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and General Symptoms</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling.
Solicited general symptoms assessed were fatigue, headache, malaise and fever (defined as oral/axillary/tympanic temperature equal to or above 37.5 degrees Celsius).</description>
        <time_frame>Within 7 days (Days 0-6) after vaccination</time_frame>
        <population>The Intention To Treat cohort for the analysis of safety included all vaccinated subject for whom safety data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Herpes Simplex Virus Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and General Symptoms</title>
          <description>Solicited local symptoms assessed were pain, redness and swelling.
Solicited general symptoms assessed were fatigue, headache, malaise and fever (defined as oral/axillary/tympanic temperature equal to or above 37.5 degrees Celsius).</description>
          <population>The Intention To Treat cohort for the analysis of safety included all vaccinated subject for whom safety data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4488"/>
                <count group_id="O2" value="3662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3902"/>
                    <measurement group_id="O2" value="2559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1621"/>
                    <measurement group_id="O2" value="702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1371"/>
                    <measurement group_id="O2" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2031"/>
                    <measurement group_id="O2" value="1503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1885"/>
                    <measurement group_id="O2" value="1456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1459"/>
                    <measurement group_id="O2" value="1003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400"/>
                    <measurement group_id="O2" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Grade 3 Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling.
Grade 3 pain = pain that prevented normal activities.
Grade 3 redness/swelling = redness/swelling above 30 mm and persisting for more than 24 hours</description>
        <time_frame>Within 7 days (Days 0-6) after vaccination</time_frame>
        <population>The Intention To Treat cohort for the analysis of safety included all vaccinated subject for whom safety data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Herpes Simplex Virus Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Grade 3 Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed were pain, redness and swelling.
Grade 3 pain = pain that prevented normal activities.
Grade 3 redness/swelling = redness/swelling above 30 mm and persisting for more than 24 hours</description>
          <population>The Intention To Treat cohort for the analysis of safety included all vaccinated subject for whom safety data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4488"/>
                <count group_id="O2" value="3662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Grade 3 and Related Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed were fatigue, headache, malaise and fever (oral/axillary/tympanic).
Grade 3 headache, fatigue, malaise = symptom that prevented normal activities.
Grade 3 fever = temperature above 39.0 degrees Celsius.
Related = symptom assessed by the investigator as causally related to the vaccination</description>
        <time_frame>Within 7 days (Days 0-6) after vaccination</time_frame>
        <population>The Intention To Treat cohort for the analysis of safety included all vaccinated subject for whom safety data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Herpes Simplex Virus Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Grade 3 and Related Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed were fatigue, headache, malaise and fever (oral/axillary/tympanic).
Grade 3 headache, fatigue, malaise = symptom that prevented normal activities.
Grade 3 fever = temperature above 39.0 degrees Celsius.
Related = symptom assessed by the investigator as causally related to the vaccination</description>
          <population>The Intention To Treat cohort for the analysis of safety included all vaccinated subject for whom safety data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4488"/>
                <count group_id="O2" value="3662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue related to vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1776"/>
                    <measurement group_id="O2" value="1286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache related to vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1523"/>
                    <measurement group_id="O2" value="1171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise related to vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1225"/>
                    <measurement group_id="O2" value="816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever related to vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295"/>
                    <measurement group_id="O2" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AEs have been tabulated for a 31-day period. An unsolicited AE was any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
        <time_frame>Within 31 days after vaccination</time_frame>
        <population>The Intention To Treat cohort for the analysis of safety included all vaccinated subject for whom safety data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Herpes Simplex Virus Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AEs have been tabulated for a 31-day period. An unsolicited AE was any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.</description>
          <population>The Intention To Treat cohort for the analysis of safety included all vaccinated subject for whom safety data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4488"/>
                <count group_id="O2" value="3662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2154"/>
                    <measurement group_id="O2" value="1677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With New Onset Chronic Diseases (NOCDs), Medically Significant Conditions (MSCs) and Serious Adverse Events (SAEs)</title>
        <description>NOCDs included adverse events (AEs) as autoimmune disorders, asthma, type I diabetes, allergies. MSCs included AEs prompting emergency room or physician visits unrelated to common diseases or routine visits for physical examination or vaccination, or SAEs unrelated to common diseases. SAEs included medical occurrences either life-threatening, requiring hospitalization, or resulting in death, disability/incapacity or congenital anomaly/birth defect in a subject’s offspring. Common diseases included upper respiratory infections (URIs), sinusitis, pharyngitis, gastroenteritis, urinary tract infection, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury. The following were not reported if not considered as SAEs and occurring more than 30 days post vaccination: URIs, sinusitis, pharyngitis, gastroenteritis, injury, or visits for routine physical examination or vaccination. AEs are described, using Medical Dictionary for Regulatory Activities’ preferred terms.</description>
        <time_frame>Throughout the study (From Month 0 up to Month 20)</time_frame>
        <population>The Intention To Treat cohort for the analysis of safety included all vaccinated subject for whom safety data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Herpes Simplex Virus Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With New Onset Chronic Diseases (NOCDs), Medically Significant Conditions (MSCs) and Serious Adverse Events (SAEs)</title>
          <description>NOCDs included adverse events (AEs) as autoimmune disorders, asthma, type I diabetes, allergies. MSCs included AEs prompting emergency room or physician visits unrelated to common diseases or routine visits for physical examination or vaccination, or SAEs unrelated to common diseases. SAEs included medical occurrences either life-threatening, requiring hospitalization, or resulting in death, disability/incapacity or congenital anomaly/birth defect in a subject’s offspring. Common diseases included upper respiratory infections (URIs), sinusitis, pharyngitis, gastroenteritis, urinary tract infection, cervico-vaginal yeast infections, menstrual cycle abnormalities and injury. The following were not reported if not considered as SAEs and occurring more than 30 days post vaccination: URIs, sinusitis, pharyngitis, gastroenteritis, injury, or visits for routine physical examination or vaccination. AEs are described, using Medical Dictionary for Regulatory Activities’ preferred terms.</description>
          <population>The Intention To Treat cohort for the analysis of safety included all vaccinated subject for whom safety data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4488"/>
                <count group_id="O2" value="3662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NOCDs/MSCs/SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abortion spontaneous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypothyroidism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appendicitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicide attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ovarian cyst</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningitis viral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dehydration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nephrolithaiasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature labor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyelonephritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Road traffic accident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin laceration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abortion missed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abortion spontaneous complete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bipolar disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression suicidal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crohn's disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperemesis gravidarum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperthyroidism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed included medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or were a congenital anomaly/birth defect in a subject’s offspring.</description>
        <time_frame>Throughout the study (From Month 0 up to Month 20)</time_frame>
        <population>The Intention To Treat cohort for the analysis of safety included all vaccinated subject for whom safety data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Herpes Simplex Virus Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Havrix Group</title>
            <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed included medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or were a congenital anomaly/birth defect in a subject’s offspring.</description>
          <population>The Intention To Treat cohort for the analysis of safety included all vaccinated subject for whom safety data were available.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4488"/>
                <count group_id="O2" value="3662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and general symptoms: during the 7-day (Day 0-6) follow-up period after vaccination. Unsolicited adverse events: during the 31 days following vaccination period. Serious adverse events: from Month 0 up to Month 20</time_frame>
      <desc>Related SAEs were reported for 6 and 5 subjects in the Herpes Simplex Virus and Havrix groups, respectively. 1 fatal SAE was reported for 1 subject in the Herpes Simplex Virus Group, and assessed by the investigator as not related to vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Herpes Simplex Virus Group</title>
          <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of herpes simplex virus vaccine (HSV) intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
        </group>
        <group group_id="E2">
          <title>Havrix Group</title>
          <description>Females between, and including, 18 and 30 years of age at the time of first vaccination who received 3 doses of the investigational formulation of Havrix vaccine intramuscularly in the non-dominant deltoid on a 0, 1, 6 month schedule.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <description>This SAE was assessed the investigators as related to study vaccination for one subject in the Havrix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <description>This SAE was assessed the investigators as related to study vaccination for one subject in the Havrix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arnold-chiari malformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Heart disease congenital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidic goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <description>This SAE was assessed the investigators as related to study vaccination for one subject in the Havrix Group.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>This SAE was assessed the investigators as related to study vaccination for one subject in the Herpes Simplex Virus Group.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Appendix disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Crohn’s disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Death neonatal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <description>This SAE was fatal and assessed by the investigators as not related to study vaccination.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <description>This SAE was assessed the investigators as related to study vaccination for one subject in the Havrix Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <description>This SAE was assessed the investigators as related to study vaccination for one subject in the Havrix Group.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Fitz-hugh-curtis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Chlamydial cervicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Chorioamnionitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Corneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pneumococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Tick-borne fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Toxic shock syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Vaginal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Respiratory fume inhalation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Water intoxication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <description>This SAE was assessed the investigators as related to study vaccination for one subject in the Herpes Simplex Virus Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Neurofibrosarcoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Teratoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <description>This SAE was assessed the investigators as related to vaccination for 2 and one subjects in the Herpes Simplex Virus and Havrix groups, respectively.</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Cerebral cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Complicated migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Ophthalmoplegic migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Stupor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <description>This SAE was assessed the investigators as related to study vaccination for one subject in the Herpes Simplex Virus Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Premature separation of placenta</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Foetal growth retardation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pregnancy induced hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Bipolar i disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Bipolar ii disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis minimal lesion</sub_title>
                <description>This SAE was assessed the investigators as related to study vaccination for one subject in the Herpes Simplex Virus Group.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Ureteral polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Ovarian haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lichen sclerosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Prophylaxis against hiv infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Removal of foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3902" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2559" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3902" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="2559" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="1621" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="702" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1371" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="438" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2031" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1503" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1885" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1456" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1459" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1003" subjects_at_risk="3662"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="400" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="260" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2154" subjects_at_risk="4488"/>
                <counts group_id="E2" subjects_affected="1677" subjects_at_risk="3662"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Out of the 8323 subjects enrolled and vaccinated, 7850 subjects were followed throughout the study, e. a. for safety and adverse event assessment (4488 in the Herpes Simplex Virus Group and 3662 in the Havrix Group).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

